Oncologist, writer, award-winning ‘How This is Building Me’ Onclive podcast host - fan of truth, creativity and humor
https://podcasts.apple.com/us/podcast/how-this-is-building-me/id1726421043
D. Ross Camidge
Loading...
After multiple requests from various people I let myself be a guest on my own podcast with Dr Erin Schenk as guest host. She dug deeper and in different directions than others
A tale of two tkis. Lorlatinib prevents new brain Mets. Based on intracranial Duration of Response neladalkib (admittedly in later line) doesn’t show the same flat line. Anti-ntrk’s cns protective effect separate from driver oncogene status is writ large. Still hiding in plain sight
As we exchanged how, as physicians, we had to be honest about our own experiences with marijuana, to destigmatize talking about it with patients we joked about not having tried chemotherapy either. At least for me that would change in the next three years
It just means our eyes are open
The very talented Lisa Goldman sent me this watercolor earlier this year. She chose a poppy as they grow in disturbed ground and are beautiful. The sentiment is true for all of us, a diagnosis of cancer might emphasize this but it doesn’t own this thought
Live today. I got to be a voice on paul wheatley-price’s podcast. Ive known paul a long time and it was a very relaxed exploration of my dual role as expert and lung cancer patient. With a little bad language included for fun! on.soundcloud.com/EOQ898foSFG9...
The recent podcast with Paul Wheatley-Price made me go back to our pod on lung cancer and cannabis. on.soundcloud.com/fcHAs9Vuuq2U...
High PDL1 in ALK not only does not predict for IO responsivity, but also alters tki outcomes. TKI and immune system impact are not mutually exclusive with driver oncogenes. www.clinical-lung-cancer.com/article/S152...
Recently live on HTIBM - Schenk and Me podcasts.apple.com/us/podcast/h...
